Kura Oncology, which is developing in-licensed protein inhibitors for solid tumors and blood cancers, raised $50 million by offering 6.25 million shares at $8 per share. The biotech, which is uplisting from the OTCQB (symbol: KURO), had last filed to raise $60 million by offering 3.75 million shares at its then-traded price of $16. Kura Oncology plans to list on the Nasdaq under the symbol KURA. Citi and Leerink Partners acted as lead managers on the deal.
